Latest & greatest articles for tiotropium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on tiotropium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on tiotropium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for tiotropium

1. Tiotropium (Spiriva Respimat) - as add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year

Tiotropium (Spiriva Respimat) - as add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year Published 14 January 2019 www.scottishmedicines.org.uk Product update SMC2118 tiotropium 2.5 microgram solution for inhalation (Spiriva® Respimat®) Boehringer Ingelheim Limited 7 December 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product (...) and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following an abbreviated submission tiotropium (Spiriva® Respimat®) is accepted for use within NHSScotland. Indication under review: as add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year. Tiotropium has previously been accepted for use

2019 Scottish Medicines Consortium

2. Tiotropium (Spiriva Respimat) add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma

Tiotropium (Spiriva Respimat) add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma Tiotropium (Spiriva ® Respimat ® ). Reference number 1882. Page 1 of 3 AWMSG Secretariat Assessment Report – Limited submission Tiotropium (Spiriva ® Respimat ® ) 2.5 microgram, inhalation solution Company: Boehringer Ingelheim Ltd Licensed indication under consideration: add-on maintenance bronchodilator treatment in patients aged 6 years to < 18 years with severe (...) asthma who experienced one or more severe asthma exacerbations in the preceding year Date of licence extension: 12 April 2018 Comparator(s) The company stated that there is no comparator and that tiotropium (Spiriva ® Respimat ® ) is an add-on treatment. Limited submission details ? The limited submission criteria were met based on a minor licence extension. Clinical effectiveness ? Tiotropium (Spiriva ® Respimat ® ) was recommended by the All Wales Medicines Strategy Group in 2017 as an add

2018 All Wales Medicines Strategy Group

3. Tiotropium

Tiotropium Top results for tiotropium - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for tiotropium The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

2018 Trip Latest and Greatest

4. Braltus (tiotropium): risk of inhalation of capsule if placed in the mouthpiece of the inhaler

Braltus (tiotropium): risk of inhalation of capsule if placed in the mouthpiece of the inhaler Braltus (tiotropium): risk of inhalation of capsule if placed in the mouthpiece of the inhaler - GOV.UK GOV.UK uses cookies to make the site simpler. Search Braltus (tiotropium): risk of inhalation of capsule if placed in the mouthpiece of the inhaler Train patients to place the Braltus capsule in the correct chamber of the Zonda inhaler. We have received reports of patients who have inhaled a Braltus (...) in the inhaler) and to always check the mouthpiece is clear before inhaling pharmacists dispensing Braltus capsules should remind patients to always read the in the package leaflet and that they must never place a capsule directly into the mouthpiece please continue to report adverse incidents during use of the inhaler as well as suspected adverse reactions to the medicine on a Background Braltus tiotropium 10 µg per delivered dose inhalation powder is a once-a-day maintenance bronchodilator treatment

2018 MHRA Drug Safety Update

5. Tiotropium (Spiriva Respimat) - as a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD)

Tiotropium (Spiriva Respimat) - as a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD) Published 11 December 2017 Product Update tiotropium 2.5 microgram inhalation solution (Spiriva Respimat ® ) SMC No 411/07 Boehringer Ingelheim Ltd 10 November 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use (...) in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated resubmission tiotropium (Spiriva Respimat ® ) is accepted for use within NHS Scotland. Indication under review: as a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD). Tiotropium (Spiriva Respimat ® ) was previously accepted for restricted use in patients who have poor manual dexterity and therefore have difficulty using the HandiHaler device

2017 Scottish Medicines Consortium

6. Tiotropium (Spiriva Respimat) - asthma

Tiotropium (Spiriva Respimat) - asthma %PDF-1.5 %���� 1 0 obj >>> endobj 2 0 obj > endobj 3 0 obj >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 595.32 841.92] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x���n���݀���bQ�{�E!�v��M/��>$}�%��%*��?�o /�5A�j�Z�#�B��H���'�tW^{�*@�BG)lE*ND d ���ٸ$�B���0*�:@�������@HnB+� N,������L'z�؏q�Y� ��A`���ïF䏍K��c��5:�'�5� ��x�� d��$�x�{���ʩ����rZ>*�ܒ%&�;��y�&zu��O��Y.3$!e۠i�{2�o��^��7�I@���ֲ҆,1�3�� w� �F�W9^���qA

2017 All Wales Medicines Strategy Group

7. Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease. (PubMed)

Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease. BACKGROUND: Patients with mild or moderate chronic obstructive pulmonary disease (COPD) rarely receive medications, because they have few symptoms. We hypothesized that long-term use of tiotropium would improve lung function and ameliorate the decline in lung function in patients with mild or moderate COPD. METHODS: In a multicenter, randomized, double-blind, placebo-controlled trial that was conducted in China, we randomly (...) assigned 841 patients with COPD of Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 1 (mild) or 2 (moderate) severity to receive a once-daily inhaled dose (18 μg) of tiotropium (419 patients) or matching placebo (422) for 2 years. The primary end point was the between-group difference in the change from baseline to 24 months in the forced expiratory volume in 1 second (FEV 1 ) before bronchodilator use. Secondary end points included the between-group difference in the change from

2017 NEJM

8. Spiolto Respimat (tiotropium/olodaterol) - chronic obstructive pulmonary disease (COPD)

Spiolto Respimat (tiotropium/olodaterol) - chronic obstructive pulmonary disease (COPD) Spiolto Respimat® (tiotropium/olodaterol) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Spiolto Respimat® (tiotropium/olodaterol) Conclusion Spiolto Respimat® (tiotropium/olodaterol) combines a long-acting muscarinic antagonist (LAMA) with a long-acting beta agonist (LABA) and is approved for maintenance bronchodilator treatment to relieve symptoms in adult (...) patients with chronic obstructive pulmonary disease (COPD). The LAMA component, tiotropium (Spiriva®), and the LABA component, olodaterol (Striverdi®), each have the same indication as Spiolto Respimat®. Despite statistically significant differences in several patient-specific measures of effectiveness (e.g. quality of life) favouring Spiolto Respimat® over the individual components, the efficacy is assessed to have limited clinical relevance in patients not yet started on relevant symptom-alleviating

2017 Danish Pharmacotherapy Reviews

9. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD

Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD 28424359 2017 04 20 2017 04 20 1399-3003 49 4 2017 Apr The European respiratory journal Eur. Respir. J. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD. 1601348 10.1183/13993003.01348-2016 Two replicate, double-blind, 6-week, incomplete-crossover studies (MORACTO 1 and 2) assessed the effects of tiotropium/olodaterol on inspiratory capacity (...) and exercise endurance time in patients with moderate to severe chronic obstructive pulmonary disease.For each patient, four of five treatments were administered once daily for 6 weeks, with a 21-day washout between treatments: tiotropium/olodaterol 2.5/5 µg or 5/5 µg, tiotropium 5 µg, olodaterol 5 µg or placebo, all via the Respimat inhaler. Primary outcomes were inspiratory capacity prior to exercise and exercise endurance time during constant work-rate cycle ergometry to symptom limitation at 75

Full Text available with Trip Pro

2017 EvidenceUpdates

10. A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma

A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma 27811070 2016 11 04 2017 02 24 1399-3003 49 1 2017 Jan The European respiratory journal Eur. Respir. J. A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma. 1601100 10.1183/13993003.01100-2016 We present results from the first phase III trial of once-daily tiotropium add-on to inhaled corticosteroids (ICS) plus one or more controller therapies in adolescents (...) with severe symptomatic asthma.In this double-blind, parallel-group trial (NCT01277523), 392 patients aged 12-17 years were randomised to receive once-daily tiotropium 5 µg or 2.5 µg, or placebo, as an add-on to ICS plus other controller therapies over 12 weeks. The primary and key secondary end-points were change from baseline (response) in peak forced expiratory volume in 1 s (FEV1) within 3 h post-dosing (FEV1(0-3h)) and trough FEV1, respectively, after 12 weeks of treatment.Tiotropium 5 µg provided

Full Text available with Trip Pro

2017 EvidenceUpdates

11. Tiotropium/olodaterol - Addendum

Tiotropium/olodaterol - Addendum 1 Translation of addendum A15-57 Tiotropium/Olodaterol – Addendum zum Auftrag A15-31 (Version 1.0; Status: 14 January 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 14 January 2016 1.0 Commission: A15-57 Version: Status: IQWiG Reports – Commission No. A15-57 Tiotropium/olodaterol – Addendum to Commission A15-31 1 (...) Addendum A15-57 Version 1.0 Tiotropium/olodaterol – Addendum to Commission A15-31 14 January 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Tiotropium/olodaterol – Addendum to Commission A15-31 Commissioning agency: Federal Joint Committee Commission awarded on: 22 December 2015 Internal Commission No.: A15-57 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im

2016 Institute for Quality and Efficiency in Healthcare (IQWiG)

12. [Tiotropium/olodaterol - addendum to commission A15-31]

[Tiotropium/olodaterol - addendum to commission A15-31] Tiotropium/olodaterol: addendum zum auftrag A15-31; auftrag A15-57 [Tiotropium/olodaterol - addendum to commission A15-31] Tiotropium/olodaterol: addendum zum auftrag A15-31; auftrag A15-57 [Tiotropium/olodaterol - addendum to commission A15-31] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Tiotropium/olodaterol: addendum zum auftrag A15-31; auftrag A15-57. [Tiotropium/olodaterol - addendum to commission A15-31] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 358. 2016 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Benzoxazines; Bronchodilator Agents; Humans; Scopolamine

2016 Health Technology Assessment (HTA) Database.

13. Chronic obstructive pulmonary disease: tiotropium/olodaterol (Spiolto Respimat)

Chronic obstructive pulmonary disease: tiotropium/olodaterol (Spiolto Respimat) Chronic obstructiv Chronic obstructive pulmonary disease: e pulmonary disease: tiotropium/olodaterol (Spiolto Respimat) tiotropium/olodaterol (Spiolto Respimat) Evidence summary Published: 10 May 2016 nice.org.uk/guidance/esnm72 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in May 2016. See summaries of product characteristics (SPCs (...) ), British national formulary (BNF) or the MHRA or NICE websites for up- to-date information. Summary Compared with its individual mono-components, a combination of tiotropium/olodaterol (Spiolto Respimat) has shown statistically significant improvements in lung function and health-related quality of life outcomes, although the clinical relevance of these improvements is unclear. There are no published studies which directly compare the efficacy and safety of tiotropium/olodaterol with other long-acting

2016 National Institute for Health and Clinical Excellence - Advice

14. Tiotropium add-on therapy in adolescents with moderate asthma: A 1-year randomized controlled trial (PubMed)

Tiotropium add-on therapy in adolescents with moderate asthma: A 1-year randomized controlled trial 26960245 2016 08 07 2017 06 15 2017 06 15 1097-6825 138 2 2016 Aug The Journal of allergy and clinical immunology J. Allergy Clin. Immunol. Tiotropium add-on therapy in adolescents with moderate asthma: A 1-year randomized controlled trial. 441-450.e8 10.1016/j.jaci.2016.01.011 S0091-6749(16)00186-X Results from phase III clinical trials in adults and phase II clinical trials in children (...) and adolescents demonstrate that tiotropium is an effective treatment when added to inhaled corticosteroid (ICS) maintenance therapy. We sought to assess the efficacy and safety of once-daily tiotropium Respimat added to ICSs with or without a leukotriene receptor antagonist in a phase III trial in adolescent patients with moderate symptomatic asthma. In this 48-week, double-blind, placebo-controlled, parallel-group study, 398 patients aged 12 to 17 years were randomized to receive 5 μg (2 puffs of 2.5 μg

Full Text available with Trip Pro

2016 EvidenceUpdates

15. [Tiotropium/olodaterol: benefit assessment according to §35a Social Code Book V (dossier assessment)]

[Tiotropium/olodaterol: benefit assessment according to §35a Social Code Book V (dossier assessment)] Tiotropium/olodaterol – nutzenbewertung gemäß § 35a SGB V [Tiotropium/olodaterol: benefit assessment according to §35a Social Code Book V (dossier assessment)] Tiotropium/olodaterol – nutzenbewertung gemäß § 35a SGB V [Tiotropium/olodaterol: benefit assessment according to §35a Social Code Book V (dossier assessment)] IQWiG Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Tiotropium/olodaterol – nutzenbewertung gemäß § 35a SGB V. [Tiotropium/olodaterol: benefit assessment according to §35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 337. 2015 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Benzoxazines

2016 Health Technology Assessment (HTA) Database.

16. Tiotropium/olodaterol (Spiolto Respimat) - maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Tiotropium/olodaterol (Spiolto Respimat) - maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). Published 09 November 2015 Product Update: tiotropium/olodaterol 2.5 microgram/ 2.5 microgram inhalation solution (Spiolto ® Respimat ® ) SMC No. (1099/15) Boehringer Ingelheim Ltd 9 October 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug (...) and Therapeutic Committees (ADTCs) on its use in Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission tiotropium/olodaterol (Spiolto ® Respimat ® ) is accepted for use within NHS Scotland. Indication under review: maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). Spiolto ® Respimat ® should be used in patients for whom tiotropium and olodaterol are appropriate choices of antimuscarinic and long

2015 Scottish Medicines Consortium

17. Tiotropium / olodaterol (Inspiolto Respimat)

Tiotropium / olodaterol (Inspiolto Respimat) Tiotropium / olodaterol | CADTH.ca Find the information you need Tiotropium / olodaterol Tiotropium / olodaterol Last Updated: May 6, 2015 Result type: Reports Project Number: SR0436-000 Product Line: Generic Name: Tiotropium / olodaterol Brand Name: Inspiolto Respimat Manufacturer: Boehringer Ingelheim (Canada) Ltd. Indications: Chronic Obstructive Pulmonary Disease (COPD) Submission Type: New Project Status: Active Date Recommendation Issued

2015 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

18. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4) (PubMed)

Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4) 25573406 2015 04 01 2015 12 31 2017 02 20 1399-3003 45 4 2015 Apr The European respiratory journal Eur. Respir. J. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). 969-79 10.1183/09031936.00136014 Efficacy and safety of tiotropium+olodaterol fixed-dose combination (FDC) compared with the mono-components was evaluated in patients with moderate to very severe (...) chronic obstructive pulmonary disease (COPD) in two replicate, randomised, double-blind, parallel-group, multicentre, phase III trials. Patients received tiotropium+olodaterol FDC 2.5/5 μg or 5/5 μg, tiotropium 2.5 μg or 5 μg, or olodaterol 5 μg delivered once-daily via Respimat inhaler over 52 weeks. Primary end points were forced expiratory volume in 1 s (FEV1) area under the curve from 0 to 3 h (AUC0-3) response, trough FEV1 response and St George's Respiratory Questionnaire (SGRQ) total score at 24 weeks. In total, 5162

Full Text available with Trip Pro

2015 EvidenceUpdates

19. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study (PubMed)

Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study 25677679 2015 03 13 2015 06 09 2015 11 19 1468-3296 70 4 2015 Apr Thorax Thorax Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non (...) -inferiority study. 311-9 10.1136/thoraxjnl-2014-206345 QVA149 is a once-daily (o.d.) inhaled dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium for the treatment of COPD. The QUANTIFY study compared QVA149 with a free-dose bronchodilator combination of tiotropium plus formoterol (TIO+FOR) in improving health-related quality of life (HRQoL) of patients with COPD. This multicentre, blinded, triple-dummy

Full Text available with Trip Pro

2015 EvidenceUpdates

20. Tiotropium delivered via Respimat compared with Handihaler: no significant difference in mortality in TIOSPIR trial

Tiotropium delivered via Respimat compared with Handihaler: no significant difference in mortality in TIOSPIR trial Tiotropium delivered via Respimat compared with Handihaler: no significant difference in mortality in TIOSPIR trial Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Tiotropium delivered via Respimat compared with Handihaler: no significant difference in mortality in TIOSPIR trial From: Updated: 16 February 2015 Published: 12 February 2015 (...) Therapeutic area: Take the risk of cardiovascular side effects into account when prescribing tiotropium delivered via Respimat or Handihaler to patients with certain cardiac conditions, who were excluded from clinical trials of tiotropium (including TIOSPIR). When using tiotropium delivered via Respimat or Handihaler to treat chronic obstructive pulmonary disease (COPD): take the risk of cardiovascular side effects into account for patients with conditions that may be affected by the anticholinergic

2015 MHRA Drug Safety Update